Alí Duarte-García1,2, Ying Ying Leung1,2, Laura C Coates1,2, Dorcas Beaton1,2, Robin Christensen1,2, Ethan T Craig1,2, Maarten de Wit1,2, Lihi Eder1,2, Lara Fallon1,2, Oliver FitzGerald1,2, Dafna D Gladman1,2, Niti Goel1,2, Richard Holland1,2, Chris Lindsay1,2, Lara Maxwell1,2, Philip Mease1,2, Ana Maria Orbai1,2, Beverley Shea1,2, Vibeke Strand1,2, Douglas J Veale1,2, William Tillett1,2, Alexis Ogdie3,4. 1. From the Division of Rheumatology, Department of Medicine, and the Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota; Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Division of Rheumatology, Duke University School of Medicine, Durham, North Carolina; Kezar Life Sciences, South San Francisco; Amgen Inc., Thousand Oaks, California; Swedish-Providence-St. John's Health Systems and University of Washington, Seattle, Washington; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore; University of Leeds, Leeds; University of Oxford, Oxford; Royal National Hospital for Rheumatic Diseases; University of Bath, Bath, UK; Musculoskeletal Health and Outcomes Research, St. Michael's Hospital; Institute for Work and Health; Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto; Department of Medicine, University of Toronto, Women's College Hospital; Department of Medicine, University of Toronto, Toronto Western Hospital, Toronto; Cochrane Musculoskeletal Group, Ottawa Hospital Research Institute, Centre for Practice-Changing Research; School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario; Pfizer Inc., Montreal, Quebec, Canada; Musculoskeletal Statistics Unit: The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen; Department of Rheumatology, Odense University Hospital, Odense, Denmark; Department of Medical Humanities, Patient Research Partner, Amsterdam University Medical Centre, Amsterdam, the Netherlands; Department of Rheumatology, St. Vincent's University Hospital; Conway Institute for Biomolecular Research, University College Dublin, Ireland; Royal Prince Alfred Hospital Medical Centre, Sydney, Australia. 2. A. Duarte-García, MD, Division of Rheumatology, Department of Medicine, Mayo Clinic, and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic; Y.Y. Leung, MD, MBChB, Department of Rheumatology and Immunology, Singapore General Hospital; L.C. Coates, PhD, MBChB, University of Leeds, and University of Oxford; D. Beaton, PhD, MSc, BScOT, Musculoskeletal Health and Outcomes Research, St. Michael's Hospital, and Institute for Work and Health, and Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto; R. Christensen, PhD, MSc, Musculoskeletal Statistics Unit: The Parker Institute, Bispebjerg and Frederiksberg Hospital, and Department of Rheumatology, Odense University Hospital; E.T. Craig, MD, MPH, Division of Rheumatology, Department of Medicine, University of Pennsylvania; M. de Wit, PhD, Department of Medical Humanities, Patient Research Partner, Amsterdam University Medical Centre; L. Eder, MD, PhD, Department of Medicine, University of Toronto, Women's College Hospital; L. Fallon, PhD, Pfizer Inc.; O. FitzGerald, MD, MBChB, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, Department of Medicine, University of Toronto, Toronto Western Hospital; N. Goel, MD, Patient Research Partner, Division of Rheumatology, Duke University School of Medicine, and Kezar Life Sciences; R. Holland, MBChB, Royal Prince Alfred Hospital Medical Centre; C. Lindsay, PharmD, Patient Research Partner, Amgen Inc.; L. Maxwell, PhD, Cochrane Musculoskeletal Group, Ottawa Hospital Research Institute, Centre for Practice-Changing Research; P. Mease, MD, Swedish-Providence-St. John's Health Systems and University of Washington; A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; B. Shea, PhD, Ottawa Hospital Research Institute, and School of Epidemiology and Public Health, University of Ottawa; V. Strand, MD, Biopharmaceutical Consultant; D.J. Veale, MD, St. Vincent's University Hospital, and University College Dublin; W. Tillett, PhD, MBChB, Royal National Hospital for Rheumatic Diseases, and the University of Bath; A. Ogdie, MD, MSCE, Division of Rheumatology, Department of Medicine, University of Pennsylvania. Dr. Duarte-García and Dr. Leung are co-first authors. W. Tillett and Dr. Ogdie are co-senior authors. 3. From the Division of Rheumatology, Department of Medicine, and the Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota; Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Division of Rheumatology, Duke University School of Medicine, Durham, North Carolina; Kezar Life Sciences, South San Francisco; Amgen Inc., Thousand Oaks, California; Swedish-Providence-St. John's Health Systems and University of Washington, Seattle, Washington; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore; University of Leeds, Leeds; University of Oxford, Oxford; Royal National Hospital for Rheumatic Diseases; University of Bath, Bath, UK; Musculoskeletal Health and Outcomes Research, St. Michael's Hospital; Institute for Work and Health; Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto; Department of Medicine, University of Toronto, Women's College Hospital; Department of Medicine, University of Toronto, Toronto Western Hospital, Toronto; Cochrane Musculoskeletal Group, Ottawa Hospital Research Institute, Centre for Practice-Changing Research; School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario; Pfizer Inc., Montreal, Quebec, Canada; Musculoskeletal Statistics Unit: The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen; Department of Rheumatology, Odense University Hospital, Odense, Denmark; Department of Medical Humanities, Patient Research Partner, Amsterdam University Medical Centre, Amsterdam, the Netherlands; Department of Rheumatology, St. Vincent's University Hospital; Conway Institute for Biomolecular Research, University College Dublin, Ireland; Royal Prince Alfred Hospital Medical Centre, Sydney, Australia. alexis.ogdie@uphs.upenn.edu. 4. A. Duarte-García, MD, Division of Rheumatology, Department of Medicine, Mayo Clinic, and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic; Y.Y. Leung, MD, MBChB, Department of Rheumatology and Immunology, Singapore General Hospital; L.C. Coates, PhD, MBChB, University of Leeds, and University of Oxford; D. Beaton, PhD, MSc, BScOT, Musculoskeletal Health and Outcomes Research, St. Michael's Hospital, and Institute for Work and Health, and Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto; R. Christensen, PhD, MSc, Musculoskeletal Statistics Unit: The Parker Institute, Bispebjerg and Frederiksberg Hospital, and Department of Rheumatology, Odense University Hospital; E.T. Craig, MD, MPH, Division of Rheumatology, Department of Medicine, University of Pennsylvania; M. de Wit, PhD, Department of Medical Humanities, Patient Research Partner, Amsterdam University Medical Centre; L. Eder, MD, PhD, Department of Medicine, University of Toronto, Women's College Hospital; L. Fallon, PhD, Pfizer Inc.; O. FitzGerald, MD, MBChB, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, Department of Medicine, University of Toronto, Toronto Western Hospital; N. Goel, MD, Patient Research Partner, Division of Rheumatology, Duke University School of Medicine, and Kezar Life Sciences; R. Holland, MBChB, Royal Prince Alfred Hospital Medical Centre; C. Lindsay, PharmD, Patient Research Partner, Amgen Inc.; L. Maxwell, PhD, Cochrane Musculoskeletal Group, Ottawa Hospital Research Institute, Centre for Practice-Changing Research; P. Mease, MD, Swedish-Providence-St. John's Health Systems and University of Washington; A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; B. Shea, PhD, Ottawa Hospital Research Institute, and School of Epidemiology and Public Health, University of Ottawa; V. Strand, MD, Biopharmaceutical Consultant; D.J. Veale, MD, St. Vincent's University Hospital, and University College Dublin; W. Tillett, PhD, MBChB, Royal National Hospital for Rheumatic Diseases, and the University of Bath; A. Ogdie, MD, MSCE, Division of Rheumatology, Department of Medicine, University of Pennsylvania. Dr. Duarte-García and Dr. Leung are co-first authors. W. Tillett and Dr. Ogdie are co-senior authors. alexis.ogdie@uphs.upenn.edu.
Abstract
OBJECTIVE: The Psoriatic Arthritis (PsA) Core Domain Set for randomized controlled trials and longitudinal observational studies has recently been updated. The joint counts are central to the measurement of the peripheral arthritis component of the musculoskeletal (MSK) disease activity domain. We report the Outcome Measures in Rheumatology (OMERACT) 2018 meeting's approaches to seek endorsement of the 66/68 swollen and tender joint count (SJC66/TJC68) for inclusion in the PsA Core Outcome Measurement Set (COS). METHODS: Using the OMERACT Filter 2.1 Instrument Selection Process, the SJC66/TJC68 was assessed for (1) domain match, (2) feasibility, (3) numerical sense (construct validity), and (4) discrimination (test retest reliability, longitudinal construct validity, sensitivity in clinical trials, and thresholds of meaning). A protocol was designed to assess the measurement properties of the SJC66/TJC68 joint count. The results were summarized in a Summary of Measurement Properties table developed by OMERACT. OMERACT members discussed and voted on whether the strength of the evidence supported that the SJC66/TJC68 had passed the OMERACT Filter as an outcome measurement instrument for the PsA COS. RESULTS: OMERACT delegates endorsed the use of the SJC66/TJC68 for the measurement of the peripheral arthritis component of the MSK disease activity domain. Among patient research partners, 100% voted for a "green" endorsement, whereas among the group of other stakeholders, 88% voted for a "green" endorsement. CONCLUSION: The SJC66/TJC68 is the first fully endorsed outcome measurement instrument using the OMERACT Filter 2.1 and the first instrument fully endorsed within the PsA COS.
OBJECTIVE: The Psoriatic Arthritis (PsA) Core Domain Set for randomized controlled trials and longitudinal observational studies has recently been updated. The joint counts are central to the measurement of the peripheral arthritis component of the musculoskeletal (MSK) disease activity domain. We report the Outcome Measures in Rheumatology (OMERACT) 2018 meeting's approaches to seek endorsement of the 66/68 swollen and tender joint count (SJC66/TJC68) for inclusion in the PsA Core Outcome Measurement Set (COS). METHODS: Using the OMERACT Filter 2.1 Instrument Selection Process, the SJC66/TJC68 was assessed for (1) domain match, (2) feasibility, (3) numerical sense (construct validity), and (4) discrimination (test retest reliability, longitudinal construct validity, sensitivity in clinical trials, and thresholds of meaning). A protocol was designed to assess the measurement properties of the SJC66/TJC68 joint count. The results were summarized in a Summary of Measurement Properties table developed by OMERACT. OMERACT members discussed and voted on whether the strength of the evidence supported that the SJC66/TJC68 had passed the OMERACT Filter as an outcome measurement instrument for the PsA COS. RESULTS: OMERACT delegates endorsed the use of the SJC66/TJC68 for the measurement of the peripheral arthritis component of the MSK disease activity domain. Among patient research partners, 100% voted for a "green" endorsement, whereas among the group of other stakeholders, 88% voted for a "green" endorsement. CONCLUSION: The SJC66/TJC68 is the first fully endorsed outcome measurement instrument using the OMERACT Filter 2.1 and the first instrument fully endorsed within the PsA COS.
Authors: William Tillett; Ana-Maria Orbai; Alexis Ogdie; Ying Ying Leung; Vibeke Strand; Dafna D Gladman; Philip J Mease; Laura C Coates Journal: Ann Rheum Dis Date: 2017-07-26 Impact factor: 19.103
Authors: Monika Schoels; Daniel Aletaha; Julia Funovits; Arthur Kavanaugh; Daniel Baker; Josef S Smolen Journal: Ann Rheum Dis Date: 2010-06-04 Impact factor: 19.103
Authors: Carlo Salvarani; Giampiero Girolomoni; Vito Di Lernia; Paolo Gisondi; Giovanni Tripepi; Colin Gerard Egan; Antonio Marchesoni Journal: Semin Arthritis Rheum Date: 2016-06-21 Impact factor: 5.532
Authors: Alexis Ogdie; Maarten de Wit; Kristina Callis Duffin; Willemina Campbell; Jeffrey Chau; Laura C Coates; Lihi Eder; Musaab Elmamoun; Oliver FitzGerald; Dafna D Gladman; Niti Goel; Jana James; Umut Kalyoncu; John Latella; Chris Lindsay; Philip J Mease; Denis O'Sullivan; Ingrid Steinkoenig; Vibeke Strand; William Tillett; Ana-Maria Orbai Journal: J Rheumatol Date: 2017-05 Impact factor: 4.666
Authors: M Englbrecht; Y Wang; M Ronneberger; B Manger; N Vastesaeger; D J Veale; G Schett Journal: Arthritis Care Res (Hoboken) Date: 2010-07 Impact factor: 4.794
Authors: Maarten Boers; John R Kirwan; George Wells; Dorcas Beaton; Laure Gossec; Maria-Antonietta d'Agostino; Philip G Conaghan; Clifton O Bingham; Peter Brooks; Robert Landewé; Lyn March; Lee S Simon; Jasvinder A Singh; Vibeke Strand; Peter Tugwell Journal: J Clin Epidemiol Date: 2014-02-28 Impact factor: 6.437
Authors: Ana-Maria Orbai; Maarten de Wit; Philip J Mease; Kristina Callis Duffin; Musaab Elmamoun; William Tillett; Willemina Campbell; Oliver FitzGerald; Dafna D Gladman; Niti Goel; Laure Gossec; Pil Hoejgaard; Ying Ying Leung; Chris Lindsay; Vibeke Strand; Désirée M van der Heijde; Bev Shea; Robin Christensen; Laura Coates; Lihi Eder; Neil McHugh; Umut Kalyoncu; Ingrid Steinkoenig; Alexis Ogdie Journal: J Rheumatol Date: 2017-02-01 Impact factor: 4.666
Authors: Cecilia A C Prinsen; Sunita Vohra; Michael R Rose; Maarten Boers; Peter Tugwell; Mike Clarke; Paula R Williamson; Caroline B Terwee Journal: Trials Date: 2016-09-13 Impact factor: 2.279
Authors: Ana-Maria Orbai; Maarten de Wit; Philip Mease; Judy A Shea; Laure Gossec; Ying Ying Leung; William Tillett; Musaab Elmamoun; Kristina Callis Duffin; Willemina Campbell; Robin Christensen; Laura Coates; Emma Dures; Lihi Eder; Oliver FitzGerald; Dafna Gladman; Niti Goel; Suzanne Dolwick Grieb; Sarah Hewlett; Pil Hoejgaard; Umut Kalyoncu; Chris Lindsay; Neil McHugh; Bev Shea; Ingrid Steinkoenig; Vibeke Strand; Alexis Ogdie Journal: Ann Rheum Dis Date: 2016-09-09 Impact factor: 19.103
Authors: Alicia García-Dorta; Paola León-Suarez; Sonia Peña; Marta Hernández-Díaz; Carlos Rodríguez-Lozano; Enrique González-Dávila; María Vanesa Hernández-Hernández; Federico Díaz-González Journal: Front Med (Lausanne) Date: 2022-01-13